OTLK
Outlook Therapeutics Inc.
Company Overview
| Mkt Cap | $219.87M | Price | $1.58 |
| Volume | 20.62M | Change | -4.24% |
| P/E Ratio | -3.5 | Open | $1.62 |
| Revenue | $1.4M | Prev Close | $1.65 |
| Net Income | $-62.4M | 52W Range | $0.16 - $3.39 |
| Div Yield | N/A | Target | $5.50 |
| Overall | 48 | Value | 40 |
| Quality | 21 | Technical | 83 |
No chart data available
About Outlook Therapeutics Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Latest News
Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA
Outlook Therapeutics Resubmits FDA Application for ONS-5010
Outlook Therapeutics Resubmits FDA Application for ONS-5010
Outlook Therapeutics Announces Insider-Backed Direct Stock Offering
Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OTLK | $1.58 | -4.2% | 20.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Outlook Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW